Response andTolerability of Sofosbuvir Plus Velpatasvir in PatientsWith Hepatitis C Related LiverCirrhosis

Abstract

Objective: To determine the response and tolerability of Sofosbuvir plusVelpatasvirin patients with hepatitis C related liver cirrhosis in the studied Pakistani population. Our study also compared cirrhotic patients with non-cirrhotic ones in terms of treatment effectiveness as well as safety.
Material and Methods: This was a prospective observational study performed at Department of Medicine, Hepatology and Gastroen-terology, SIMS/Services hospital, Lahore, from January 2022 to December 2022. The enrolled 100 patients were grouped into Group A (non-cirrhotic hepatitis C patients) and Group B (compensated cirrhotic hepatitis C patients). Sofosbuvir plus Velpatasvir was given to groupApatientsfor 12 weeks & to group B patients for 24 weeks. Laboratory findings, response and adverse effects were recorded
four weekly. The data was analysed using SPSS version 27. Comparisons were done between two studied patient's groups in terms of effectiveness and tolerability of the treatment. The p-values were significant if <0.05.
Results: ETR and SVR-12 were 98.1% and 94.3% in group Aand 95.7% and 93.6% in group B. SVR-12 was  comparable in two groups (p= 0.602). No adverse event leading to treatment withdrawal was reported in eithergroup.However,mildworseningof abdominal wasseeninonepatientofgroupB(p=0.470).Deterioration in blood indices was seen in 2 patients of group B while 3 patients of group A (P= 0.557). Mild ALT flare was seen in one patient of each group (p= 0.722).
Conclusion: Sofosbuvir plus Velpatasvir therapy was highly efficacious and safe in non-cirrhotic and compensated cirrhotic patients with chronic viral hepatitis C. The response and tolerability of treatment was comparable in both studied groups.